# EDGAR Filing Document

**Accession Number:** 0001113423
**File Stem:** 0001493152-26-024635
**Filing Date:** 2026-5
**Character Count:** 24772
**Document Hash:** d7c853ea7d7b9f34884dc34d83411345
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-024635.hdr.sgml**: 20260520

**ACCESSION NUMBER**: 0001493152-26-024635

**CONFORMED SUBMISSION TYPE**: SC 13E3/A

**PUBLIC DOCUMENT COUNT**: 110

**FILED AS OF DATE**: 20260520

**DATE AS OF CHANGE**: 20260520

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** COSCIENS Biopharma Inc.
- **CENTRAL INDEX KEY:** 0001113423
- **STANDARD INDUSTRIAL CLASSIFICATION:** PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS [2844]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A6
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 13E3/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-51184
- **FILM NUMBER:** 261004735

**BUSINESS ADDRESS:**
- **STREET 1:** C/O NORTON ROSE FULBRIGHT CANADA LLP
- **STREET 2:** 222 BAY STREET, SUITE 3000, PO BOX 53
- **CITY:** TORONTO
- **STATE:** A6
- **ZIP:** M5K 1E7
- **BUSINESS PHONE:** 843-900-3201

**MAIL ADDRESS:**
- **STREET 1:** C/O NORTON ROSE FULBRIGHT CANADA LLP
- **STREET 2:** 222 BAY STREET, SUITE 3000, PO BOX 53
- **CITY:** TORONTO
- **STATE:** A6
- **ZIP:** M5K 1E7

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Aeterna Zentaris Inc.
- **DATE OF NAME CHANGE:** 20040617

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AETERNA LABORATORIES INC
- **DATE OF NAME CHANGE:** 20000503
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** COSCIENS Biopharma Inc.
- **CENTRAL INDEX KEY:** 0001113423
- **STANDARD INDUSTRIAL CLASSIFICATION:** PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS [2844]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A6
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 13E3/A

**BUSINESS ADDRESS:**
- **STREET 1:** C/O NORTON ROSE FULBRIGHT CANADA LLP
- **STREET 2:** 222 BAY STREET, SUITE 3000, PO BOX 53
- **CITY:** TORONTO
- **STATE:** A6
- **ZIP:** M5K 1E7
- **BUSINESS PHONE:** 843-900-3201

**MAIL ADDRESS:**
- **STREET 1:** C/O NORTON ROSE FULBRIGHT CANADA LLP
- **STREET 2:** 222 BAY STREET, SUITE 3000, PO BOX 53
- **CITY:** TORONTO
- **STATE:** A6
- **ZIP:** M5K 1E7

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Aeterna Zentaris Inc.
- **DATE OF NAME CHANGE:** 20040617

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AETERNA LABORATORIES INC
- **DATE OF NAME CHANGE:** 20000503

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Amendment No. 4 to** 

**SCHEDULE 13E-3**

**Rule 13e-3 Transaction Statement<br> (Pursuant to Section 13(e) of the Securities Exchange Act of 1934)**

**COSCIENS Biopharma Inc.**

(Name of the Issuer)

**COSCIENS Biopharma Inc.**<br> (Name of Persons Filing Statement)

**Common Stock, No Par Value per Share**

(Title of Class of Securities)

**22112H101**

(CUSIP Number of Class of Securities)

---

| | |
|:---|:---|
| **Peter Puccetti** |  |
| **Interim CEO and Chairman of the Board** |  |
| COSCIENS Biopharma Inc. | **Scott Saks** |
| **Telephone: (843) 900-3223** | **Norton Rose Fulbright US LLP** |
| **E-mail:** | **1301 Avenue of the Americas** |
| **c/o Borden Ladner Gervais, LLP,** | **New York, New York 10019-6022** |
| **22 Adelaide Street West, Suite 3400,** | **United States** |
| **Toronto ON M5H 4E3, Canada** | **(212) 318-3151** |

---

(Name, Address, and Telephone Number of Person Authorized to Receive Notices and Communication on<br> Behalf of Person(s) Filing Statement)

This statement is filed in connection with (check the appropriate box):

a. ☒ The
 filing of solicitation materials or an information statement Notice subject to Regulation 14A, Regulation 14C or Rule 13e-3(c) under
 the Securities Exchange Act of 1934.

b. ☐ The
 filing of a registration statement under the Securities Act of 1933.

c. ☐ A
 tender offer.

d. ☐ None
 of the above.

Check the following box if the soliciting materials or information statement referred to in checking box (a) are preliminary copies: ☐

Check the following box if the filing is a final amendment reporting the results of the transaction: ☐

**Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of this transaction, passed upon the merits or fairness of this transaction, or passed upon the adequacy or accuracy of the disclosure in this transaction statement on Schedule 13E-3. Any representation to the contrary is a criminal offense.**

**INTRODUCTION**

This Amendment No. 4 amends and supplements the Rule 13e-3 Transaction Statement on Schedule 13E-3 that was filed by COSCIENS Biopharma Inc. (referred to herein as "**Company**" or "**subject company**" or "**filing person**") with the Securities and Exchange Commission (the "**Commission**") on April 4, 2026, as amended by Amendment No. 1 filed on May 4, 2026, Amendment No. 2 filed on May 8, 2026, and Amendment No. 3 filed on May 12, 2026 (the "**Transaction Statement**").

This Amendment No. 4 to the Transaction Statement is accompanied by a Notice of Annual and Special Meeting of Shareholders and Management Proxy Circular (the "**Circular**"), distributed to holders of common shares of the Company, no par value per share ("**Common Shares**"), in connection with an annual and special meeting of the shareholders of the Company anticipated to be held on June 17, 2026. Simultaneously with the filing of this Statement, the Company has filed as exhibits to a Form 6-K, dated May 20, 2026, the Circular and final form of proxy distributed to the Company's shareholders.

At such meeting, the shareholders of the Company will vote upon a special resolution, which, if adopted, will authorize amendments to the Company's articles to: (i) consolidate the Common Shares on the basis of one (1) post-Consolidation Common Share for every 150 pre-Consolidation Common Shares (the "**Consolidation Ratio"**"); and (ii) immediately following the Consolidation, split the post-Consolidation Common Shares on the basis of 50 Common Shares for every one (1) post-Consolidation Common Share (collectively, the "Share Capital Amendment"). Shareholders with positions representing a number of Common Shares less than the Consolidation Ratio (individually, and not in the aggregate) will cease to hold such Common Shares and will be entitled to receive an amount in cash per pre-Consolidation Common Share equal to U.S.$1.60 (the "**Consolidation Consideration**"), rounded down to the nearest whole cent.

**INCORPORATION BY REFERENCE**

The cross-references below are being supplied pursuant to General Instruction G to Schedule 13E-3 and show the location in the Circular of the information required to be included in response to the items of Schedule 13E-3. In accordance with General Instruction F to Schedule 13E-3, the information set forth in the Circular filed as an exhibit hereto is incorporated herein by reference in response to Items 1-15 of this Statement, in the manner and to the extent specified below.

**Item 1. Summary Term Sheet.**

The information set forth in the Circular in the section entitled "Summary of Matters to be Acted Upon" is incorporated herein by reference.

**Item 2. Subject Company Information.**

&nbsp;&nbsp;&nbsp;&nbsp;(a) *Name and Address*. COSCIENS Biopharma Inc.'s executive offices are located at c/o Borden Ladner Gervais, LLP, 22 Adelaide Street
 West, Suite 3400, Toronto, Ontario, Canada M5H 4E3. The Company's telephone number is (843) 900-3223.

(b) *Securities*.
 As of March 24, 2026, the Company had 3,184,155 common shares, no par value per share (the "**Common Shares** "), outstanding.
 Each Common Share is entitled to one vote.

(c) *Trading market and price*. The information set forth in the Circular in the section entitled "Share Capital Amendment – Trading
 in Common Shares" is incorporated herein by reference.

(d) *Dividends*.
 The information set forth in the Circular in the section entitled "Share Capital Amendment – Dividends" is incorporated
 herein by reference.

(e) *Prior public offerings*. The Company has not made any underwritten public offering of its Common Shares during the past three years.

(f) *Prior stock purchases*. The Company has not purchased any Common Shares during the past two years.

**Item 3. Identity and Background of Filing Person.**

&nbsp;&nbsp;&nbsp;&nbsp;(a) *Name and address*. The filing person is COSCIENS Biopharma Inc., the subject company. The address and telephone number of the filing
 person is the same as included with respect to the subject company in Item 2 above. The information set forth in the Company's
 Form 20-F for the year ended December 31, 2025, originally filed on March 25, 2026, in the section entitled "Item 6. Directors,
 Senior Management and Employees," including the name of each director and the name and title of each executive officer of the
 Company, is incorporated herein by reference.

(b) *Business and background of entities*. The information set forth in the Circular in the section entitled "Additional Information –
 The Corporation" is incorporated herein by reference.

(c) *Business and background of natural persons*. The information set forth in the Circular in the sections entitled "Additional Information
 – Directors and Executive Officers" and "– The Corporation" are incorporated herein by reference. None
 of the directors or executive officers of the Company was convicted in a criminal proceeding during the past five years excluding
 traffic violations or similar misdemeanors) or was a party to any judicial or administrative proceeding during the past five years
 (except for matters that were dismissed without sanction or settlement) that resulted in a judgment, decree or final order enjoining
 the person from future violations of, or prohibiting activities subject to, federal or state securities laws, or a finding of any
 violation of federal or state securities laws.

**Item 4. Terms of the Transaction.**

&nbsp;&nbsp;&nbsp;&nbsp;(a) *Material Terms*. The information set forth in the Circular in the section entitled "Share Capital Amendment" is incorporated
 herein by reference.

(c) *Different terms*. The information set forth in the Circular in the section entitled "Share Capital Amendment – Effects of the
 Share Capital Amendment – Effects on the Corporation" is incorporated herein by reference.

(d) *Dissenters' rights*. Under the Canada Business Corporation Act (the "**CBCA** "), shareholders are not entitled to exercise
 any statutory dissent rights under the CBCA with respect to the proposed Share Capital Amendment.

(e) *Provisions for unaffiliated stockholders*. None.

(f) *Eligibility for listing or trading.* The information set forth in the Circular in the sections entitled "Share Capital Amendment –
 Substantive and Procedural Factors Considered by the Board as to the Fairness of the Share Capital Amendment – Substantive
 Factors Disfavouring the Share Capital Amendment – Inability to participate in future increase in value of Common Shares"
 and "– Cessation of Exchange Act Reporting" are incorporated herein by reference.

**Item 5. Past Contacts, Transactions, Negotiations and Agreements.**

&nbsp;&nbsp;&nbsp;&nbsp;(a) *Transactions.* The information set forth in the Circular in the sections entitled "Interest of Informed Persons in Material Transactions;
 Related Party Transactions" and "Share Capital Amendment – Past Contacts, Transactions, Negotiations and Agreements
 with Related Parties" are incorporated herein by reference.

(b) *Significant corporate events.* The information set forth in the Circular in the section entitled "Share Capital Amendment – Past
 Contacts, Transactions, Negotiations and Agreements with Related Parties" is incorporated herein by reference.

(c) *Negotiations or contacts.* The information set forth in the Circular in the section entitled "Share Capital Amendment – Past Contacts,
 Transactions, Negotiations and Agreements with Related Parties" is incorporated herein by reference.

(e) *Agreements involving the subject company's securities.* The information set forth in the Circular in the section entitled "Share
 Capital Amendment – Past Contacts, Transactions, Negotiations and Agreements with Related Parties" is incorporated herein
 by reference.

**Item 6. Purposes of the Transaction and Plans or Proposals.**

&nbsp;&nbsp;&nbsp;&nbsp;(a) *Purpose.* The information set forth in the Circular in the section entitled "Share Capital Amendment – Purposes of the Transaction
 and Plans or Proposals" is incorporated herein by reference.

(b) *Use of Securities Acquired.* The information set forth in the Circular in the section entitled "Share Capital Amendment –
 Purposes of the Transaction and Plans or Proposals" is incorporated herein by reference.

(c) *Plans*.
 The information set forth in the Circular in the sections entitled "Share Capital Amendment – Purposes of the Transaction
 and Plans or Proposals," "Share Capital Amendment – Effects of the Share Capital Amendment," "Share
 Capital Amendment – Substantive and Procedural Factors Considered by the Board as to the Fairness of the Share Capital Amendment
 – Disfavouring the Share Capital Amendment – Inability to participate in future increase in value of Common Shares"
 and "– Cessation of Exchange Act Reporting," are incorporated herein by reference.

**Item 7. Purposes, Alternatives, Reasons and Effects.**

&nbsp;&nbsp;&nbsp;&nbsp;(a) *Purposes.* The information set forth in the Circular in the sections entitled "Share Capital Amendment – Background and Reasons
 for the Share Capital Amendment; Purpose, Effects, and Alternatives" and "Share Capital Amendment – Purpose"
 are incorporated herein by reference.

(b) *Alternatives.* The information set forth in the Circular in the section entitled "Share Capital Amendment – Alternatives Considered
 by the Board" is incorporated herein by reference.

(c) *Reasons.* The information set forth in the Circular in the sections entitled "Share Capital Amendment – Background and Reasons
 for the Share Capital Amendment; Purpose, Effects, and Alternatives," "Share Capital Amendment – Alternatives Considered
 by the Board," and "Share Capital Amendment – Substantive and Procedural Factors Considered by the Board as to
 the Fairness of the Share Capital Amendment" are incorporated herein by reference.

(d) *Effects.* The information set forth in the Circular in the sections entitled "Share Capital Amendment – Effects of the Share
 Capital Amendment" and "Share Capital Amendment – Substantive and Procedural Factors Considered by the Board as
 to the Fairness of the Share Capital Amendment" are incorporated herein by reference.

**Item 8. Fairness of the Transaction.**

&nbsp;&nbsp;&nbsp;&nbsp;(a) *Fairness.* The information set forth in the Circular in the sections entitled "Summary Term Sheet – Board Fairness Determination
 and Board Approval," "Share Capital Amendment – Substantive and Procedural Factors Considered by the Board as to
 the Fairness of the Share Capital Amendment – Procedural Factors Favoring the Share Capital Amendment – Approval by the
 Board," and "Share Capital Amendment – Solicitation or Recommendation" are incorporated herein by reference.

(b) *Factors Considered in Determining Fairness.* The information set forth in the Circular in the sections entitled "Share Capital Amendment
 – Segal Fairness Opinion" and "Share Capital Amendment – Substantive and Procedural Factors Considered by
 the Board as to the Fairness of the Share Capital Amendment" are incorporated herein by reference.

(c) *Approval of Security Holders.* The information set forth in the Circular in the section entitled "Share Capital Amendment –
 Substantive and Procedural Factors Considered by the Board as to the Fairness of the Share Capital Amendment – Procedural Factors
 Favoring the Share Capital Amendment – Approval by the Board" is incorporated herein by reference.

(d) *Unaffiliated Representative.* The information set forth in the Circular in the section entitled "Share Capital Amendment – Segal
 Fairness Opinion" is incorporated herein by reference.

(e) *Approval of Directors.* The information set forth in the Circular in the section entitled "Share Capital Amendment – Substantive
 and Procedural Factors Considered by the Board as to the Fairness of the Share Capital Amendment – Procedural Factors Favoring
 the Share Capital Amendment – Approval by the Board" is incorporated herein by reference.

(f) *Other Offers.* Not applicable.

**Item 9. Reports, Opinions, Appraisals, and Negotiations.**

&nbsp;&nbsp;&nbsp;&nbsp;(a) *Report, opinion or appraisal.* The information set forth in the Circular in the sections entitled "Share Capital Amendment –
 Segal Fairness Opinion" and "Additional Information – Where to Find Information" are incorporated herein
 by reference.

(b) *Preparer and summary of the report, opinion or appraisal.* The information set forth in the Circular in the sections listed in Item 9(a)
 above are incorporated herein by reference.

(c) *Availability of documents.* The information set forth in the Circular in the section entitled "Additional Information – Where to
 Find Information" is incorporated herein by reference.

**Item 10. Source and Amounts of Funds or Other Consideration.**

&nbsp;&nbsp;&nbsp;&nbsp;(a) *Source of funds*. The information set forth in the Circular in the section entitled "Share Capital Amendment – Source of
 Funds" is incorporated herein by reference.

(b) *Conditions*.
 Not applicable.

(c) *Expenses*.
 The information set forth in the Circular in the sections entitled "Share Capital Amendment – Source of Funds"
 is incorporated herein by reference.

(d) *Borrowed funds*. Not applicable.

**Item 11. Interest in Securities of the Subject Company.**

&nbsp;&nbsp;&nbsp;&nbsp;(a) *Securities Ownership*. The information set forth in the Circular in the section entitled "Share Capital Amendment – Interest
 in Securities of the Corporation" is incorporated herein by reference.

(b) *Securities Transactions.* There has not been any transaction by the Company in the Common Shares during the past 60 days.

**Item 12. The Solicitation or Recommendation.**

&nbsp;&nbsp;&nbsp;&nbsp;(d) *Intent to tender or vote in a going-private transaction.* The information set forth in the Circular in the sections entitled "Share
 Capital Amendment – Substantive and Procedural Factors Considered by the Board as to the Fairness of the Share Capital Amendment
 – Procedural Factors Favoring the Share Capital Amendment – Approval by the Board" and "Share Capital Amendment
 – Solicitation or Recommendation" are incorporated herein by reference.

(e) *Recommendations of others*. The information set forth in the Circular in the sections entitled "Share Capital Amendment – Substantive
 and Procedural Factors Considered by the Board as to the Fairness of the Share Capital Amendment – Procedural Factors Favoring
 the Share Capital Amendment – Approval by the Board" and "Share Capital Amendment – Solicitation or Recommendation"
 are incorporated herein by reference.

**Item 13. Financial Information.**

&nbsp;&nbsp;&nbsp;&nbsp;(a) *Financial information*. The audited financial statements of the Company for the two years ended December 31, 2024 and 2025 are incorporated
 herein by reference to the Company's Form 20-F for the year ended December 31, 2025, originally filed on March 25, 2026 (see
 page F-1 and the following pages). The condensed interim consolidated financial statements as of March 31, 2026 and for the three-month
 periods ended March 31, 2026 and 2025, are incorporated by reference to Exhibit 99.1 to the current report on Form 6-K furnished
 by the Company to the Commission on May 12, 2026. The information set forth in the Circular in the section entitled "Share
 Capital Amendment – Financial Information" is incorporated herein by reference.

(b) *Pro forma information*. The information set forth in the Circular in the section entitled "Share Capital Amendment – Financial
 Information – Pro Forma Information" is incorporated herein by reference.

**Item 14. Persons / Assets, Retained, Employed, Compensated or Used.**

&nbsp;&nbsp;&nbsp;&nbsp;(a) *Solicitations or recommendations*. The information set forth in the Circular in the sections entitled "Share Capital Amendment –
 Segal Fairness Opinion" and "Share Capital Amendment – Solicitation or Recommendation" are incorporated herein
 by reference.

(b) *Employees and corporate assets*. The information set forth in the Circular in the section entitled "Share Capital Amendment –
 Source of Funds" is incorporated herein by reference.

**Item 15. Additional Information.**

&nbsp;&nbsp;&nbsp;&nbsp;(b) *Other material information.* Not applicable.

**Item 16. Exhibits.**

---

| | |
|:---|:---|
| (a)(2)(i) | [Notice of Annual and Special Meeting of Shareholders and Management Proxy Circular, dated May 18, 2026 (incorporated by reference to Exhibit 99.1 to the Company's Form 6-K dated May 20, 2026, filed by the Company with the Securities and Exchange Commission on May 20, 2026.](exa2-i.htm) |
| (a)(2)(ii) | [Form of Proxy.](exa2-ii.htm) |
| (a)(2)(iii) | [Letter of Transmittal.](exa2-iii.htm) |
| (a)(2)(iv) | [Press Release issued by the Company, dated April 20, 2026, incorporated herein by reference to Exhibit 99.2 to the Report on Form 6-K furnished by the Company to the Commission on April 20, 2026.\*](https://www.sec.gov/Archives/edgar/data/1113423/000149315226020983/exa2-iv.htm) |
| (b) | Not applicable. |
| (c) | [Fairness Opinion of Segal dated as of April 16, 2026.\*](https://www.sec.gov/Archives/edgar/data/1113423/000149315226020983/exc.htm) |
| (d) | Not applicable. |
| (f) | Not applicable. |
| (g) | Not applicable. |
| 107 | [Filing Fee Table.\*](https://www.sec.gov/Archives/edgar/data/1113423/000149315226018001/ex107.htm) |

---

\* *Previously filed.* 

**SIGNATURES**

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Transaction Statement is true, complete, and correct.

---

| | |
|:---|:---|
| COSCIENS BIOPHARMA INC. | COSCIENS BIOPHARMA INC. |
| By: | */s/ Giuliano La Fratta* |
| Name: | Giuliano La Fratta |
| Title: | Chief Financial Officer |

---

Dated: May 20, 2026

## Ex-99.(A)(2)(I)

**Exhibit (a)(2)(i)**

![](exa2-i_001.jpg)

![](exa2-i_002.jpg)

![](exa2-i_003.jpg)

![](exa2-i_004.jpg)

![](exa2-i_005.jpg)

![](exa2-i_006.jpg)

![](exa2-i_007.jpg)

![](exa2-i_008.jpg)

![](exa2-i_009.jpg)

![](exa2-i_010.jpg)

![](exa2-i_011.jpg)

![](exa2-i_012.jpg)

![](exa2-i_013.jpg)

![](exa2-i_014.jpg)

![](exa2-i_015.jpg)

![](exa2-i_016.jpg)

![](exa2-i_017.jpg)

![](exa2-i_018.jpg)

![](exa2-i_019.jpg)

![](exa2-i_020.jpg)

![](exa2-i_021.jpg)

![](exa2-i_022.jpg)

![](exa2-i_023.jpg)

![](exa2-i_024.jpg)

![](exa2-i_025.jpg)

![](exa2-i_026.jpg)

![](exa2-i_027.jpg)

![](exa2-i_028.jpg)

![](exa2-i_029.jpg)

![](exa2-i_030.jpg)

![](exa2-i_031.jpg)

![](exa2-i_032.jpg)

![](exa2-i_033.jpg)

![](exa2-i_034.jpg)

![](exa2-i_035.jpg)

![](exa2-i_036.jpg)

![](exa2-i_037.jpg)

![](exa2-i_038.jpg)

![](exa2-i_039.jpg)

![](exa2-i_040.jpg)

![](exa2-i_041.jpg)

![](exa2-i_042.jpg)

![](exa2-i_043.jpg)

![](exa2-i_044.jpg)

![](exa2-i_045.jpg)

![](exa2-i_046.jpg)

![](exa2-i_047.jpg)

![](exa2-i_048.jpg)

![](exa2-i_049.jpg)

![](exa2-i_050.jpg)

![](exa2-i_051.jpg)

![](exa2-i_052.jpg)

![](exa2-i_053.jpg)

![](exa2-i_054.jpg)

![](exa2-i_055.jpg)

![](exa2-i_056.jpg)

![](exa2-i_057.jpg)

![](exa2-i_058.jpg)

![](exa2-i_059.jpg)

![](exa2-i_060.jpg)

![](exa2-i_061.jpg)

![](exa2-i_062.jpg)

![](exa2-i_063.jpg)

![](exa2-i_064.jpg)

![](exa2-i_065.jpg)

![](exa2-i_066.jpg)

![](exa2-i_067.jpg)

![](exa2-i_068.jpg)

![](exa2-i_069.jpg)

![](exa2-i_070.jpg)

![](exa2-i_071.jpg)

![](exa2-i_072.jpg)

![](exa2-i_073.jpg)

![](exa2-i_074.jpg)

![](exa2-i_075.jpg)

![](exa2-i_076.jpg)

![](exa2-i_077.jpg)

![](exa2-i_078.jpg)

![](exa2-i_079.jpg)

![](exa2-i_080.jpg)

![](exa2-i_082.jpg)

![](exa2-i_083.jpg)

![](exa2-i_084.jpg)

![](exa2-i_085.jpg)

![](exa2-i_086.jpg)

![](exa2-i_087.jpg)

![](exa2-i_088.jpg)

![](exa2-i_089.jpg)

![](exa2-i_081.jpg)

## Ex-99.(A)(2)(Ii)

**Exhibit (a)(2)(ii)**

![](exa2-ii_001.jpg)

![](exa2-ii_002.jpg)

## Ex-99.(A)(2)(Iii)

**Exhibit (a)(2)(iii)**

![](exa2-iii_001.jpg)

![](exa2-iii_002.jpg)

![](exa2-iii_003.jpg)

![](exa2-iii_004.jpg)

![](exa2-iii_005.jpg)

![](exa2-iii_006.jpg)

![](exa2-iii_007.jpg)

![](exa2-iii_008.jpg)

![](exa2-iii_009.jpg)

![](exa2-iii_010.jpg)

![](exa2-iii_011.jpg)

![](exa2-iii_012.jpg)

![](exa2-iii_013.jpg)

![](exa2-iii_014.jpg)

![](exa2-iii_015.jpg)